HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
| العنوان: | HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis |
|---|---|
| المؤلفون: | Antonia Consuelo Falzea, Amalia Luce, Maria Antonietta Mazzei, Giovanna Bianco, Rocco Giannicola, Eleonora Iuliano, Iris Maria Forte, Daniele Caracciolo, Luigi Pirtoli, Pierosandro Tagliaferri, Alessandra Strangio, Michele Caraglia, Rita Emilena Saladino, Paolo Tini, Pierpaolo Pastina, Antonio Giordano, Pierpaolo Correale, Andrea Sergi, Valerio Nardone, Diana Giannarelli, Pierfrancesco Tassone, Natale Daniele Calandruccio, Luciano Mutti |
| المساهمون: | Correale, P., Saladino, R. E., Giannarelli, D., Sergi, A., Mazzei, M. A., Bianco, G., Giannicola, R., Iuliano, E., Forte, I. M., Calandruccio, N. D., Falzea, A. C., Strangio, A., Nardone, V., Pastina, P., Tini, P., Luce, A., Caraglia, M., Caracciolo, D., Mutti, L., Tassone, P., Pirtoli, L., Giordano, A., Tagliaferri, P. |
| المصدر: | Cells Volume 9 Issue 9 Cells, Vol 9, Iss 1964, p 1964 (2020) |
| بيانات النشر: | MDPI, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Genes, MHC Class I, immune-related pneumoniti, immune-related pneumonitis, Article, PD-1/PD-L1 blockade, 03 medical and health sciences, 0302 clinical medicine, Cancer immunotherapy, Internal medicine, irAE, medicine, Humans, Lung cancer, lcsh:QH301-705.5, Immune Checkpoint Inhibitors, Pneumonitis, Retrospective Studies, cancer immunotherapy, business.industry, Melanoma, HLA-profile, General Medicine, Pneumonia, Middle Aged, medicine.disease, Immune checkpoint, Blockade, Radiation therapy, 030104 developmental biology, lcsh:Biology (General), 030220 oncology & carcinogenesis, irAEs, Female, Immunotherapy, business, medicine.drug |
| الوصف: | Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial cancer. Monoclonal antibodies (mAbs) against either PD-1 or PD-L1 are active agents for these patients however, their use may be complicated by unpredictable immune-related adverse events (irAEs), including immune-related pneumonitis (IRP). We carried out a retrospective multi-institutional statistical analysis to investigate clinical and biological parameters correlated with IRP rate on a cohort of 256 patients who received real-world treatment with PD-1/PD-L1 blocking mAbs. An independent radiological review board detected IRP in 29 patients. We did not find statistical IRP rate correlation with gender, tumor type, specific PD-1 or PD-L1 blocking mAbs, radiation therapy, inflammatory profile, or different irAEs. A higher IRP risk was detected only in mNSCLC patients who received metronomic chemotherapy +/&minus bevacizumab compared with other treatments prior PD-1/PD-L1 blockade. Moreover, we detected a strong correlation among the IRP rate and germinal expression of HLA-B*35 and DRB1*11, alleles associated to autoimmune diseases. Our findings may have relevant implications in predicting the IRP rate in mNSCLC patients receiving PD-1/PD-L1 blockade and need to be validated on a larger patient series. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2073-4409 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc9c929bb077dbc57de3cfcdd247b02Test http://europepmc.org/articles/PMC7564884Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5bc9c929bb077dbc57de3cfcdd247b02 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20734409 |
|---|